New proteasome inhibitors in the treatment of multiple myeloma
Vania Tietsche de Moraes Hungria, Edvan de Queiroz Crusoé, Rosane Isabel Bittencourt and 7 more
Hematology, Transfusion and Cell Therapy · 2019
doi:10.1016/j.htct.2018.07.003 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape. Keywords: Multiple myeloma, Proteasome inhibitors, Bortezomib, Ixazomib, Carfilzomib
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.